Background and Purpose-Chronic kidney disease may increase the risk for ischemic stroke or systemic embolism in patients with nonvalular atrial fibrillation (AF). We conducted a meta-analysis to summarize all published studies to investigate the link between chronic kidney disease and risk of thromboembolic events in AF. Methods-We performed a literature search using MEDLINE (source PubMed, 1966 and EMBASE (1980 to July 2014) with no restrictions. Pooled effect estimates were obtained by using random-effects meta-analysis. Results-Eighteen studies involving 538 479 patients and 41 719 incident thromboembolic events were identified. From the pooled analysis, AF patients with estimated glomerular filtration rate <60 mL/min compared with those with estimated glomerular filtration rate ≥60 mL/min experienced a significantly increased risk for developing thromboembolic events (relative risk, 1.62 [95% confidence interval, 1.40-1.87; P<0.001]). The annual rate of thromboembolic events increased by 0.41% (95% confidence interval, 0.17%-0.65%) for a 10 mL/min decrease in renal function. Addition of renal impairment to CHADS 2 slightly improved the stroke risk stratification. Conclusions-Impaired renal function is an independent predictor of stroke or systemic embolism in patients with nonvalvular AF. Consideration of renal function may improve stroke risk stratification in patients with AF. (Stroke.
A trial fibrillation (AF) has gained much attention as an independent risk factor for ischemic stroke and its association with increased mortality and morbidity. 1 Chronic kidney disease (CKD), defined as reduced glomerular filtration rate or proteinuria, markedly increases the risk of stroke by 2.1-folds, 2 risk of myocardial infarction by 2.0-folds, 3 and risk of combined cardiovascular events by 2.3-folds in the general population. 4 AF frequently coexists with CKD: about onethird of outpatients with AF have CKD, and 15% of patients with CKD have AF. There was an almost 4-fold increase in risk of AF in patients with stage 4 CKD compared with agematched and sex-matched patients without CKD. [5] [6] [7] CKD is a well-established risk factor for atherosclerotic disease, 8 but conflicting data exist about the incremental effect of CKD and its severity on the risk of ischemic stroke in the setting of AF. Although several latest studies have reported that CKD is associated with increased risk of stroke among patients with AF, 5, 9, 10 patients with renal disease were underrepresented in most trials that validated stroke risk stratification schemes, and current risk scores, such as CHADS 2 and CHA 2 DS 2 -VASc, do not include CKD as a potential risk factor for thromboembolic events. 11, 12 Therefore, there is limited information on whether moderate-severe CKD improves the predictive value of stroke risk stratification. To help resolve this uncertainty of CKD as a prognostic tool, we conducted a meta-analysis to evaluate the effect of renal function on the risk of thromboembolic events in nonvalvular AF patients and, second, to assess the additive prognostic value of moderatesevere CKD on CHADS 2 scores.
Methods

Search Strategy and Selection Criteria
We did a computerized search of English-language publications listed in the electronic databases MEDLINE (source PUBMED, 1966 to July 2014) and EMBASE (1980 to July 2014) using the following text and key words in combination both as MeSH terms and text words: renal, kidney, atrial fibrillation, ischemic stroke, thromboembolic events, randomized controlled trial, cohort studies, andprospective studies.
To minimize differences between studies, we imposed the following methodological restrictions for the inclusion criteria: (1) Studies that contained the minimum information necessary to estimate the relative risk (RR) associated with CKD, including case-control, cohort studies and randomized controlled trials published as original articles; (2) Studies in which populations were representative of patients with CKD and not those limited exclusively to patients with end-stage renal disease. In instances of multiple publications, the most up-to-date or comprehensive information was used. Citations initially selected by systematic search were first retrieved as a title
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or abstract and preliminarily screened. Potentially suitable citations were then retrieved as complete manuscripts and assessed for compliance to inclusion criteria.
Data Abstraction
Articles were reviewed and cross-checked independently by 2 authors (W.T. Zeng, X.T. Sun). Data on the following characteristics were independently extracted: author identification, year of publication, type of study design, study population, study location, numbers of disease outcomes of interest; mean duration of follow-up; type of thromboembolic event; RR with 95% confidence interval (CI), and reported adjustment for potential confounders. Corresponding author was contacted to verify the extracted data and to request data where it was unavailable from the published article. Any disagreements were resolved by consensus.
Data Analysis
Summary RRs (95% CI) and area under the curve (AUC or C-statistic) were calculated by pooling the study-specific estimates using a randomeffects model that included between-study heterogeneity because significant heterogeneity was anticipated among studies. Pooled RRs were expressed with 95% CIs. We calculated the I 2 (95% CI) statistic to assess heterogeneity across studies, 13 applying the following interpretation for I 2 : <50%, low heterogeneity; 50% to 75%, moderate heterogeneity; and >75%, high heterogeneity. 14, 15 Sensitivity analyses were performed to evaluate whether the results could have been affected markedly by using fixed-effect model, trim and fill method, and different inclusion and exclusion criteria. Subgroup analyses and meta-regression models were performed to investigate potential sources of between-study heterogeneity. Small study bias, consistent with publication bias, was assessed with funnel plot by Begg's adjusted rank correlation test and by Egger's regression asymmetry test. 16 Restricted cubic spline regression model was used to test the linearity in the relationship between renal function and the outcomes. Interations with estimated glomerular filtration rate (eGFR) were illustrated by plotting the estimated probability of 1-year events. 17 We used STATA, version 11.0 (Stata Corp), for all analyses. Statistical tests were 2-sided and used a significance level of P<0.05.
Results
Study Selection
With the search strategy, 1021 unique citations were initially retrieved. Of these, 261 articles were considered of interest, and full text was retrieved for detailed evaluation. Two hundred forty-three of these 261 articles were subsequently excluded because they included only patients with end-stage renal disease or did not provide enough data to estimate relative risk. Finally, 18 articles were eligible for inclusion ( Figure  I in the online-only Data Supplement).
Study Characteristics
Eighteen independent eligible studies reporting 538 479 patients and 41 719 incident thromboembolic events were identified. Six studies were based in Europe, 6 in Asia, 1 in North America, and 5 were multinational. Studies were published between March 2009 and April 2014. There were 10 prospective cohort studies, 5,18-26 2 retrospective studies, 9,27 and 6 randomized controlled trials. 17, [28] [29] [30] [31] [32] Of the primary studies, 100% had described independent, consecutive sampling of their cohort. Average follow-up duration ranged from 11 to 144 months. Patients were followed up for an average of over 2 years in 50% of the studies. The sizes of the cohorts ranged from 387 to 283 969, with 7 largest studies recruiting over 10 000 participants.
Of all the studies, 6 included only patients off anticoagulation 5, 23, 27, [32] [33] [34] and 6 investigated only patients taking oral anticoagulants (OACs). 17, 19, [28] [29] [30] [31] Fourteen studies reported the incidence of a composite outcome (ischemic stroke or systematic embolism) as an outcome of interest and 4 studies only reported the incidence of ischemic stroke. Fourteen studies (77.8%) provided ≥1 adjusted risk estimate, and 11 (78.6%) of them reported an adjusted estimate for CHADS 2 : congestive heart failure, hypertension, age, diabetes mellitus, stroke/transient ischemic attack. Detailed information on adjustments is reported in Table 1 . Figure 1 showed the results from the random effects model combining the RRs for thromboembolic events. Overall, patients with eGFR <60 mL/min compared with those with eGFR ≥60 mL/min experienced a significantly increased risk for developing thromboembolic events (RR, 1.62 [95% CI, 1.40-1.87; P<0.001]; Figure 1 ). There was evidence of moderate heterogeneity of RRs across these studies (I 2 , 70.85% [95% CI, 67.19-86.37; P<0.001]). These measurements of heterogeneity were likely driven by the extremely large overall number of participants in our analysis (>500 000). The point estimates of the RRs were consistently >1 in all studies, and study subgroups were more homogeneous.
CKD and Risk of Thromboembolic Events in Atrial Fibrillation
The findings from the sensitivity analyses based on different inclusion and exclusion criteria are presented in Table 2 . Risk estimates changed little after analyses with fixed-effects models, trim and fill method, or exclusion of the 2 largest and the outlier studies. Even the analysis was confined to those studies adjusted for CHADS 2 
Stratified Analyses
To explore the study heterogeneity, we performed stratified analyses across several key study characteristics and clinical factors ( Figure 2 ). We observed no significant differences across subgroups according to study type (RR, 
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Renal Function and Rate of Thromboembolic Events
In the cubic spline model that included 8 studies reporting information on event rates in varying levels of renal function, we did not find evidence suggesting any nonlinear relation between eGFR and thromboembolic risk (P for nonlinearity =0.31). A linear increase was observed in annual rate of thromboembolic events with decreasing renal function ( Figure 3 ). The rate increased by 0.41% (95% CI, 0.17-0.65) for a 10 mL/min decrease in renal function. According to the Cockcroft-Gault equation, patients with eGFR ≥80 mL/min had annual stroke or systemic embolism rates of 2.11% compared with 2.94% in patients with eGFR 50 to <80 mL/min and 4.54% in patients with eGFR <50 mL/min.
Risk Discrimination Models
Eight studies reported on changes in measures of risk discrimination on the addition of CKD to CHADS 2 prediction model. (Table 3) .
Discussion
The present meta-analysis, involving >500 000 patients and >40 000 patients with thromboembolic events from 18 studies, found a significantly increased risk of thromboembolic events associated with renal impairment in patients with AF, even after reported adjustment for CHADS 2 risk factors. The association seemed to be similar in patients taking or not taking OACs. Incidence of thromboembolic events was inversely associated with renal function, and the addition of renal impairment to CHADS 2 scores yielded a slight improvement in risk discrimination (0.03 point estimate). Recent studies have suggested that nonvalvular AF patients with heart failure (RR=1.4), hypertension (RR=1.6), older age (RR=1.4), diabetes mellitus (RR=1.7), and previous ischemic stroke (RR=2.5) were at risk of developing thromboembolic events, whereas conflicting results were reported for renal impairment. 35 This meta-analysis is the first to our knowledge to confirm CKD to be an independent risk factor for thromboembolism in patients with nonvalvular AF. Although the risk magnitude seems to be less robust than previous ischemic stroke, it is at least as strong as other well-established major risk factors, such as heart failure, hypertension, older age, diabetes mellitus. 
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one third of hemodialysis patients with AF have thromboembolic complications within 1 year of follow-up. 36 Thus, given the multifactorial nature of thromboembolism, it is highly likely that the concomitant action of CKD may be responsible for a proportion of thromboembolic events in the AF patients.
Understanding the mechanisms that underlie the association between kidney dysfunction and the risk of stroke in AF is of particular importance to help frame appropriate therapeutic decisions. First, AF per se confers a hypercoagulable state through various pathways. 37 Disorganized contraction of the atria with a decrease in atrial blood flow, endothelial and endocardial damage and dysfunction, and increased expression of tissue factor and von Willebrand factor, increased platelet activation and fibrinolysis may predispose to thrombus formation and subsequent systemic emboli. 37 Second, patients with CKD without AF is associated with a prothrombotic state, including endothelial damage, alteration in protein C metabolism, defects in the expression of glycoprotein Ib, elevated levels of various plasminogen activator inhibitor-1 and von Willebrand factor, abnormalities in various coagulation factor levels and activity, as well as inflammation. [38] [39] [40] [41] Third, CKD is further associated with abnormality of neurohormonal (eg, renin-angiotensin-aldosterone system), inflammatory, and oxidative pathways or mineral metabolism (eg, hyperparathyroidism), which may result in atherosclerosis and thus greater risk of thromboembolic events. 42 Therefore, CKD may contribute to an increased risk of ischemic stroke and other thromboembolism in AF patients by augmenting the underlying prothrombotic state through several different pathophysiological pathways.
In spite of the clear association between kidney dysfunction and thromboembolism in AF population, CKD has not been formally included in any of the current stroke stratification schemes, although it was previously proposed that the small c in CHA 2 DS 2 -VASc score could represent informally chronic renal impairment. 43 There is 1 factor that may confound the interpretation of renal impairment in AF patients. It has been proposed that renal impairment does not add much predictive value to current schemes, especially because the components of clinical scores are themselves related to renal dysfunction. For example, increasing age and heart failure are independently associated with low eGFR. 44 However, our result found that 
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renal dysfunction further increases the risk of ischemic stroke significantly after accounting for other known thromboembolic risk factors. In addition, our study demonstrated that adding renal dysfunction to the CHADS 2 score yields a small but statistically significant improvement in c-statistic. Given these findings, further studies are warranted to elucidate the additive predictive value of renal dysfunction to CHA 2 DS 2 -VASc score. Strengths of this meta-analysis include the strict inclusion criteria, the large number of patients analyzed, the robustness of the findings in sensitivity analyses, and the fact that all subgroup analyses were prespecified a priori. The absence of important publication bias supports the robustness of the study findings. A possible limitation of our study is the heterogeneity of the studies with regard to adjustment of the estimates for potential confounders. Although differences in number of events and the outcomes of interest, at least in part, explain this finding, the specific mechanism remains unclear. Inclusion of different types of studies into one meta-analysis may also introduce heterogeneity into the results. Despite this, the consistency of the finding of an increased thromboembolic risk among cohort studies and randomized controlled trials suggests that the association is valid. Another limitation was the lack of individual participant data, which precluded determining the independent associations of individual variables with study outcomes. Instead, we used between-study meta-regressions, when possible.
In conclusion, impaired renal function is a predictor of incident stroke and systemic embolism in patients with nonvalvular AF taking and not taking OACs, independent of conventional thromboembolic risk factors. Adding CKD to the CHADS 2 stroke risk scores slightly improved the risk discrimination, and consideration of renal function may improve stroke risk stratification in patients with AF.
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Table 3. AUC Analysis for 3 Risk Stratification Models in Predicting Thromboembolic Events in AF Patients
